Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp Ads (NQ: AMRN )

5.790 USD -0.200 (-3.34%)
Official Closing Price Updated: 7:58 PM EST, Mar 8, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Amarin Corp Ads

< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Amarin to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
From GlobeNewswire News Releases
Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong
From GlobeNewswire News Releases
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
From GlobeNewswire News Releases
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
From GlobeNewswire News Releases
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
From GlobeNewswire News Releases
Amarin Provides Preliminary 2020 Results and 2021 Outlook
From GlobeNewswire News Releases
Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
From GlobeNewswire News Releases
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Associatio
From GlobeNewswire News Releases
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the VASCEPA... 
From GlobeNewswire News Releases
Amarin Files Patent Infringement Lawsuit Against Hikma
From GlobeNewswire News Releases
Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)
From GlobeNewswire News Releases
Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China
From GlobeNewswire News Releases
Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Association’s Virtual Scientific Sessions 2020
From GlobeNewswire News Releases
With Growing Incidence of Brain Cancer The Brain Tumor Drug Market Could Reach $3.4 Billion in 2022
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
With Growing Incidence of Brain Cancer The Brain Tumor Drug Market Could Reach $3.4 Billion in 2022
Financialnewsmedia.com News Commentary 
From PR Newswire
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® S
From GlobeNewswire News Releases
More Comprehensive Diagnostics are Needed as Cases Surge Once More
FinancialBuzz.com News Commentary 
From PR Newswire
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
From GlobeNewswire News Releases
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Association’s Virtual Scientific Sessions 2020
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Eight Presentations, Including REDUCE-IT® CABG (Coronary Artery Bypass Graft) Results and Additional Mechanism of... 
From GlobeNewswire News Releases
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE
From GlobeNewswire News Releases
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride (TG) Levels Despite Well-Controlled Low-Density L
New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020 
From GlobeNewswire News Releases
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020
From GlobeNewswire News Releases
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Pres
From GlobeNewswire News Releases
Thinking about buying stock in Ion Geophysical, TPI Composites, Coty, Tilray, or Amarin Corp?
InvestorsObserver issues critical PriceWatch Alerts for IO, TPIC, COTY, TLRY, and AMRN. 
From PR Newswire
Thinking about buying stock in ImmunoGen, Lithium Americas Corp, Cytokinetics, Kosmos Energy, or Amarin Corp?
InvestorsObserver issues critical PriceWatch Alerts for IMGN, LAC, CYTK, KOS, and AMRN. 
From PR Newswire
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020
Data presented provides additional insight into potential mechanisms by which VASCEPA lowers cardiovascular risk 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.